Lexeo Therapeutics Current Cash

Lexeo Therapeutics's current cash stands at $72M as of March 2026. That compares with $29M in the prior-year period — up 148.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Lexeo Therapeutics reported $72M in current cash versus $29M a year earlier — a 148.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $29M in the prior-year period — up 148.2% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Lexeo Therapeutics's current cash evolved across reporting periods, while the comparison chart places LXEO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.